



Sino-American
Pharmaceutical
Professionals
Association



Title Sponsor

2026 SAPA ▶▶ HEALTHCARE INVESTMENT FORUM & ROADSHOW

Empower the Future of Global Healthcare
Cross-Border Innovation, Strategic Capital,
Accelerated AI, and Clinical Validation

Friday, June 12, 2026 | 12:30 - 7:30 pm

PWC, New York Office
300 Madison Avenue,
New York, NY 10017, USA



sapaweb.org



Registration



Venue Sponsor



Diamond Sponsor



Sino-American
Pharmaceutical
Professionals
Association

2026 SAPA HEALTHCARE INVESTMENT
FORUM & ROADSHOW

AGENDA

Time (EDT)	Session
12:30 PM – 1:00 PM	Registration
1:00 PM – 1:15 PM	Opening Remarks
1:15 PM – 1:45 PM	Keynote 1: From Margin to Mainstream: The Future of Women's Health and Future Healthcare Investment Trends
1:45 PM – 2:15 PM	Keynote 2: Pfizer Partnerships in China
2:15 PM – 2:45 PM	Keynote 3: Building First-in-Class Biotech from Science to IPO in China and Beyond
2:45 PM – 3:00 PM	Group Pictures & Coffee Break
3:00 PM – 4:10 PM	Panel Discussion 1: Investment & Entrepreneurship
4:10 PM – 4:55 PM	Company Pitches
4:55 PM – 6:05 PM	Panel Discussion 2: Business Development & M&A
6:05 PM – 6:10 PM	Closing Remarks
6:10 PM – 6:50 PM	BD Decision Intelligence: AI-Powered Drug Asset Valuation for Pharma Business Development
6:10 PM – 7:30 PM	Receptions and Networking



Expect at the Forum

- ❑ Strategic Market Insights: Gain forward-looking perspectives on global investment trends, AI-driven drug development, and cross-border innovation strategies.
- ❑ Keynote Sessions: Hear from industry leaders on investment trends, special topics in healthcare innovation, and entrepreneurial journeys including IPO success stories.
- ❑ Biotech & Healthcare Roadshow: Discover high-potential companies through curated pitch sessions featuring emerging innovators across biotech and healthcare.
- ❑ Panel Discussion: Engage in dynamic discussions on investment strategies and business development opportunities with top-tier investors and executives.
- ❑ 1:1 Partnering Opportunities: Access exclusive networking with 1:1 partnering sessions to facilitate meaningful connections.
- ❑ Networking Reception: Connect with peers, investors, and partners during an extended reception session.



Sino-American
Pharmaceutical
Professionals
Association

2026 SAPA HEALTHCARE INVESTMENT
FORUM & ROADSHOW

Empower the Future of Global Healthcare

Cross-Border Innovation, Strategic Capital,
Accelerated AI, and Clinical Validation

Keynote Sessions

Moderator



Jun (Stephen) Xue, MS
General Manager,
Chipscreen Biosciences
(US) Ltd.



Lily Li, PhD
SAPA President-Elect,
SAPA-CT Immediate Past
President



Claire Love, MBA
Partner in Deals Strategy
for Pharma and Life Sciences,
PwC



Yu (Albert) Ren, PhD
Vice President, Worldwide Business
Development China,
Pfizer



Xianping Lu, PhD
Chairman & CEO,
Chipscreen Biosciences

- ❑ PwC's latest insights show that women's healthcare is shifting from a neglected niche to a major engine of global innovation. Investment is moving toward clinical value, realworld evidence, and scalable models. Women's health, Alenabled R&D, and precision diagnostics are emerging as the most resilient, highcertainty opportunities.
- ❑ Crossborder collaboration is also reshaping the landscape. Pfizer's partnership model in China demonstrates how global resources and local execution can accelerate development and expand patient access. It's a blueprint for how innovation can move faster and farther when borders are bridges, not barriers.
- ❑ Entrepreneurs like Dr. Lu at Chipscreen show what it takes to build original innovation from the ground up — from discovery to clinical validation to global expansion. Their journeys capture the spirit of this conference.
- ❑ Today, we gather to connect science with capital, AI with clinical reality, and innovators across borders. Together, we can shape the next decade of global healthcare.



Sino-American
Pharmaceutical
Professionals
Association

2026 SAPA HEALTHCARE INVESTMENT
FORUM & ROADSHOW

Panel Discussion

Panel 1

Investment & Entrepreneurship

Moderator



Chenchao Gao, PhD MBA
Global Project Manager & Leadership
Daiichi Sankyo Inc



Issa Kildani, MS
Managing Partner,
Ambrosia Ventures



James Li, MD
Venture Partner,
Frazier Life Sciences



Rick Aldridge, MD
Managing Director,
BMO Capital Markets



Xianping Lu, PhD
Chairman & CEO,
Chipscreen Biosciences



Yingchao Zhang (YZ), PhD
Co-Founder & COO
opAlfa, Inc

- ❑ Biotech capital deployment has rebounded in 2026 with greater selectivity, as AI drives real impact in drug development and Chinese innovation fuels a surge in cross-border partnerships.
- ❑ This panel brings together leaders across venture capital, biopharma, investment banking, cross-border M&A, and enterprise AI to discuss the forces shaping the next era of healthcare investment and company building.
- ❑ Key topics include the shift toward larger, data-driven financings for differentiated assets, what defines resilient multi-product platforms in the age of AI, and how China's rise is enabling record licensing activity and new deal structures such as NewCos.
- ❑ Grounded in real-world experience, this session offers practical, actionable insights for Healthcare entrepreneurs and investors.



Sino-American
Pharmaceutical
Professionals
Association

2026 SAPA HEALTHCARE INVESTMENT
FORUM & ROADSHOW

Panel Discussion

Panel 2

Business Development & M&A

Moderator



Leon (Jun) Tang PhD
Founding Partner,
InScienceWeTrust BioAdvisory



Fernando Salles, PhD
Chief Business Officer,
Protalix Biotherapeutics



**Carla Lema Tome
PhD, MBA**
VP of Business Development,
Otsuka Pharmaceutical
Companies (U.S.)



Allan Shaw
Director,
Evecxia Therapeutics, Inc.



Blair Bu
Senior Partner,
IntelliPro



David Dai, MBA
Director,
UBS

- ❑ Gain ground-level market insights from leaders at the forefront of global BD and capital markets. Whether you are navigating macro-environmental shifts or looking to optimize your buy/sell-side strategies.
- ❑ Hot M&A Trends: Discover the modalities, disease areas, and evolving financial terms driving today's biggest deals.
- ❑ Actionable Best Practices: Learn effective strategies for sell-side biotechs, buy-side biopharma, and the vital role of brokers.
- ❑ Macro Factor Navigation: Master strategies to mitigate unpredictable variables like FDA uncertainty, MFN, and high interest rates.
- ❑ The ChinaBiotech Phenomenon: Understand how this critical factor is rapidly reshaping the global landscape.
- ❑ Networking & The Future: Explore career development in the age of AI and our expert predictions for late 2026 and beyond.



Conference co-
chairs / Moderator



Jun (Stephen) Xue, MS
General Manager,
Chipscreen Biosciences
(US) Ltd.

Jun (Stephen) Xue is the General Manager of Chipscreen Bioscience (US) Ltd., the U.S. subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SH). As the company's first U.S. employee, he leads overall operations, drives staff recruitment, and oversees the coordination of clinical, business development, and investment activities across internal teams and external partners. With more than 25 years in the pharmaceutical industry, Stephen has held roles at Roche, Sanofi, BMS, Celgene, Galderma, and Eli Lilly, contributing to multiple FDA NDAs and European MAAs across immunology, oncology, dermatology, diabetes, and cardiovascular disease. Before joining Chipscreen, Stephen launched and led entrepreneurial ventures that strengthened his expertise in business building, strategic expansion, and partnership development. He also spent several years in biotech investment, supporting the growth and financing of life science companies that ultimately reached IPO. Earlier in his career, he was part of the first wave of Merck China employees, starting in sales and marketing before moving into global roles.



Lily Li, PhD
SAPA President-Elect,
SAPA-CT Immediate Past
President

Dr. Lily Li is a seasoned Cell and Developmental Biologist with over 30 years of experience spanning research, academia, and leadership. After earning her Ph.D. in Cell and Developmental Biology, she has remained a driving force in advancing biomedical innovation, STEM education, and community engagement. Her publications have garnered wide recognition including a "Faculty of 1,000 Must Read" in Developmental Biology and the most-downloaded paper of the year in STEM CELLS. A dedicated educator and leader, she had secured and distributed multimillion-dollar grants from NASA, federal and state agencies, and private foundations, notably directed statewide NASA STEM initiatives across 26 Connecticut institutions. Beyond academia, she is deeply committed to STEM advocacy, currently serving as SAPA President-elect and SAPA-CT. Immediate past-President. During her tenure at SAPA, she has strengthened industry, academic partnerships, secured 501(c)(3) nonprofit status for SAPA-CT, and launched impactful programs such as the BioPharma Carree Bootcamp and AI Symposium. Recognized with numerous institutional honors for teaching, scholarship, and service. Dr. Li has been an advocate of SAPA community and she continues to mentor future leaders and build sustainable infrastructures that turn connections into careers and ideas into real-world impact.



Xiaodong Chen, PhD
Executive Director, Global
Head of China Strategy
and Operations
Vor Bio

Xiaodong Chen is Executive Director and Global Head of China Strategy & Operations at Vor Bio, where he leads cross-border strategic initiatives and operational integration between Vor Bio and its China partners across clinical development and operations, CMC, business development, medical affairs, regulatory affairs, quality and commercial functions. He also provides leadership for biologics drug product development, manufacturing strategy, and combination product programs supporting global development and commercialization. Prior to joining Vor Bio, Dr. Chen served as Senior Director of CMC Operations at Roivant Sciences, where he led due diligence, development, technology transfer, and manufacturing activities across multiple late-stage programs, including Telavant, Kinevant, Lysovant, Hemavant, and Affivant. Earlier in his career, he held scientific and leadership positions at Bristol Myers Squibb and contributed to the development and commercialization of approved therapies including Empliciti®, Opdualag® and Opdivo Qvantig. With nearly 15 years of experience spanning biologics development, global operations, regulatory strategy, and cross-border partnerships, Dr. Chen has extensive experience bridging scientific innovation and business execution. He has authored and co-authored numerous scientific publications, presentations, and regulatory submissions in pharmaceutical development and manufacturing. Dr. Chen received his Ph.D. from The Ohio State University and serves on the Board of the Sino-American Pharmaceutical Professionals Association (SAPA).



Keynotes



Claire Love, MBA
Partner in Deals Strategy
for Pharma and Life Sciences,
PwC

Claire has 20+ years of experience, primarily in healthcare strategy. Claire leads the overall Deals Strategy and Value Creation practice for healthcare – our team focused on commercial due diligence, operational due diligence, and value creation for private equity and corporates. Claire brings deep expertise across pharma and med tech companies as well as supporting tools, technologies, inputs, and services providers. In addition, she has worked across the women's health ecosystem from pharma to fertility to menopause to med device.

Claire earned her MBA from Harvard Business School with honors and her MPA from Harvard Kennedy School. She earned her BA from Yale University in economics and international studies. She also studied at Oxford. Prior to PwC, Claire worked at the Boston Consulting Group for a decade. Prior to her consulting career, she worked at Credit Suisse in equity research and structured credit products.



Yu (Albert) Ren, PhD
Vice President,
Worldwide Business
Development China,
Pfizer

Dr. Albert Ren leads all search and evaluation activities focused on China for Global innovations (from candidate selections through preclinical and clinical assets), and support the transaction activities and enrich Pfizer Global development pipeline.

His team continues to execute China for China BD opportunities (i.e., define strategy, search, evaluate, transact, manage alliance) to enrich Pfizer China portfolio and drive in-organic growth. In addition, Dr. Ren and his team strengthen Pfizer's engagement and influence in China innovative eco-system, fostering strategic partnerships. Dr. Ren also takes on accountability for commercial development (i.e., new product planning) in China.

Dr. Ren has over 20 years of diverse experience in the biopharmaceutical industry, management consulting, and biotech. He was previously the Chief Strategy and Corporate Development Officer at Adagene, a NASDAQ-listed clinical stage biotech company. Dr. Ren and his team oversaw strategy, business development, portfolio prioritization, commercial assessment and valuation. Prior to joining Adagene, Dr. Ren worked at Merck & Company in a variety of capacities, including pipeline valuation lead in respiratory, immunology and infectious diseases. He was the finance and portfolio lead for oncology development, contributing to the development and commercialization of KEYTRUDA®. He worked in the Corporate Strategy Office on enterprise portfolio and business development strategies, as well as in Corporate BD on a variety of transactions. Dr. Ren gained valuable business experience while working at McKinsey & Company and Quintiles/IQVIA Consulting. He worked on the development of growth strategies as well as the support of mergers and acquisitions in both the United States and China.

Dr. Ren graduated from Peking University with a bachelor's degree in chemistry and a Ph.D. in chemistry from the University of Minnesota. He also attended McKinsey's Mini-MBA program.



Keynotes



Xianping Lu, PhD
Chairman & CEO,
Chipscreen Biosciences

Dr. Xian-Ping Lu is the Founder and Chairman of Chipscreen Biosciences, a leading innovator in China's biopharmaceutical industry focused on the discovery and development of first-in-class small molecule therapeutics. Since founding the company in 2001, he has led its evolution into a pioneering force in translational science and innovative drug development, with a strong track record of bringing novel therapies from concept to commercialization.

With a career spanning over three decades across both the United States and China, Dr. Lu has played a formative role in bridging global scientific innovation with China's rapidly advancing biotech ecosystem. He previously served as Director of Research at Galderma R&D in Princeton and was among the early contributors to the establishment of Galderma Research Inc. and Maxia Pharmaceuticals in San Diego, participating in the growth of the modern biotech industry.

Dr. Lu began his scientific career in the U.S. in 1989 at the University of California, San Diego, followed by research at the La Jolla Cancer Research Foundation. He later returned to China, where he served as a visiting professor at Tsinghua University's State Key Laboratory of Biomembrane and Membrane Biotechnology, contributing to the development of cutting-edge life science research.

An accomplished scientist and entrepreneur, Dr. Lu has published over 100 peer-reviewed articles in premier journals including Nature, Science, and The Lancet, and is the lead inventor on more than 400 patents in the field of innovative therapeutics. His work has had a lasting impact on the advancement of small molecule drug discovery.

Beyond his corporate and scientific achievements, Dr. Lu is widely recognized as a key architect of China's modern biopharmaceutical innovation ecosystem. Over the past two decades, he has actively contributed to the evolution of regulatory science, drug approval pathways, healthcare reimbursement systems, and capital market frameworks, helping to enable a more innovation-driven and globally integrated industry landscape. Dr. Lu has received numerous national and industry honors and is broadly regarded as one of the trailblazers of innovative drug development in China.



Moderator (Panel 1)



Chenchao Gao, PhD, MBA
Associate Director,
Daiichi Sankyo

Dr. Chenchao Gao, PhD, MBA serves as a Global Program Manager at Daiichi Sankyo, where he leads cross-company collaboration with Merck on the development of an antibody-drug conjugate (ADC) compound. In this role, he aligns stakeholders across functions spanning clinical trials through commercialization, drives global development strategy, and advances high-value oncology assets through critical milestones.

Prior to Daiichi Sankyo, Dr. Gao was at Seagen (acquired by Pfizer), where he played a key role in obtaining global regulatory approvals for multiple oncology therapies. Earlier at Genentech, he supported IND approvals across four new indications. He began his career as a fellow at the U.S. FDA.

Dr. Gao bridges complex oncology science with high-stakes business decisions. He holds a PhD from Rutgers University and an MBA from Columbia Business School. His expertise spans clinical data, regulatory pathways and partnership economics, enabling him to assess asset value, risk, and return. His experience leading cross-company collaborations and advancing programs through commercialization positions him to structure deals, drive strategy, and execute on value creation across the healthcare sector.

Moderator (Panel 2)



Leon (Jun) Tang PhD
Founding Partner,
InScienceWeTrust
BioAdvisory

Leon 'Jun' Tang, PhD is the founding partner of InScienceWeTrust BioAdvisory (www.iswtb.com), a life sciences consulting company focused on the East-West cross-border BD&L and R&D collaborations in the pharmaceutical industry. ISWT BioAdvisory has advised 30+ biotech companies, investment funds, and other companies in the life sciences industry.

Since Feb 2026, Dr. Tang has been the Vice President of Mianus Accelerator of Mianus Capital (www.mianuscapital.com), a boutique US-based healthcare PE/VC fund currently focused on ophthalmology and also leverages a unique CRO+VC model to make early-stage investment in life sciences to drive innovation through West-East biotech collaboration.

Dr. Tang is also the founder of iSWT Community (www.iswtc.org), a US-based nonprofit that has more than 5,000 active members from the Asian biotech community.

Previously, Dr. Tang was the head of BD Search & Evaluation at Shanghai Henlius Biotech, a biotech sell-side analyst at Barclays Investment Bank, and a senior manager at the philanthropic venture fund of Cancer Research Institute of New York.

Dr. Tang has published more than 50 academic papers in prestigious journals like Nature Reviews Drug Discovery, Lancet Oncology, Science Translational Medicine, Nature Communications, Science Advances, PNAS, etc.

Dr. Tang received his bachelor's degree from Tianjin University and master's degree from Nankai University in China, a PhD degree from Icahn School of Medicine of Mount Sinai, and postdoctoral training at Memorial Sloan Kettering Cancer Center.



Panelists



Rick Aldridge, MD
Managing Director,
Healthcare Investment Banking,
BMO Capital Markets

Dr Rick Aldridge joined BMO Capital Markets in October 2025 to lead Life Sciences Investment Banking.

Previously a Managing Director at Lazard Freres & Co, leading the biopharma business in Boston.

Over the last decade, Rick has advised on transactions exceeding \$100bn in total deal value.

Rick is a qualified physician, Chartered Accountant, Chartered Tax Adviser and CFA Charter holder.



Issa Kildani, MS
Managing Partner,
Ambrosia Ventures

Issa Kildani is the Founder and Managing Partner of Ambrosia Ventures, a boutique life sciences strategy and M&A advisory firm with offices in New York and Detroit. He advises biotech, medtech, and pharmaceutical clients on sell-side and buy-side transactions, licensing, and strategic partnerships, with cross-border deal flow spanning the United States, Latin America, Middle East, South Korea, Japan, China, and Europe.

Under his leadership, Ambrosia has evolved from a focused advisory practice into an integrated intelligence company, building proprietary platforms for life sciences deal signaling. Beyond the firm, Issa serves as New York Chapter Director for VNTR, a global private investor community, where he curates and hosts investor panels and convenes founders, operators, and capital allocators across the city's innovation ecosystem.

He is based in New York with roots in Detroit, and brings to his work a sensibility shaped by cross-cultural fluency, disciplined execution, and a conviction that the best deals are built on relationships, judgment, and proprietary insight.



James Li, MD
Venture Partner,
Frazier Life Sciences

James Li is a Venture Partner at Frazier Life Sciences, where he focuses on venture creation and cross-border biotech innovation. He is Chairman of AirNexis Therapeutics, a respiratory NewCo he co-founded through the in-licensing of a PDE3/4 dual inhibitor.

Dr. Li is the co-founder and former CEO of JW Therapeutics, where he built a fully integrated cell therapy company and led the development and launch of China's first domestically developed CAR-T therapy. During his tenure, he raised over \$520 million and took the company public on the Hong Kong Stock Exchange in 2020.

Previously, he held leadership roles at Amgen, Kleiner Perkins, and Merck & Co. Dr. Li holds an M.D. from Shanghai Medical University and an M.S. in Microbiology from the University of Montana.



Panelists



Yingchao Zhang, PhD
Co-Founder & COO,
opAlda, Inc.

Dr. YZ (Yingchao Zhang) is a highly respected Chinese American community leader on the U.S. East Coast, a serial entrepreneur, and an innovative practitioner in the field of artificial intelligence. He brings more than two decades of experience spanning systems administration, cybersecurity, software engineering, and AI innovation. He currently serves as Co-founder and Chief Operating Officer of opAlda.ai, where he is dedicated to advancing enterprise AI solutions and driving their successful deployment in real-world industry applications.

Originally trained as a physicist, Dr. YZ made a decisive transition into the technology industry in 1997. Since then, he has led numerous technology innovation and digital transformation initiatives in both startup and large-enterprise environments, including significant work at NetScout serving Fortune 500 clients. He holds a Ph.D. in High Energy Nuclear Physics from the State University of New York at Stony Brook and a bachelor's degree in Low Temperature Physics from the University of Science and Technology of China. Beyond his accomplishments in technology and business, Dr. YZ is also regarded as one of the pioneers of Chinese American public service leadership in the United States.

More than a decade ago, he became actively involved in community affairs and successfully ran for local public offices, serving as both a school board member and town council member, becoming one of the few Chinese Americans to hold elected office for local government in the U.S. He has long been committed to community governance, educational equity, and cross-cultural engagement. In 2023, Dr. YZ was recognized as one of the "50 Outstanding Asian Business Leaders," and in 2025, he was appointed by Governor Phil Murphy to serve on the Board of Trustees of Thomas Edison State University. In addition to being a scientist, technologist, entrepreneur, and a dedicated public servant, he also pursues his passion for music and culture, performing with his own rock band and exemplifying a multifaceted and impactful life journey.



David Dai, MBA
Director,
UBS

David Dai is a Director in Americas Equity Research at UBS New York office. David has over fourteen years of experience in biotech/pharmaceutical industry. He spent the last seven years on the sell-side at SMBC, Barclays, and Jefferies where he covered SMID Biotechnology primarily focusing on oncology, immunology, genetic medicines, and rare diseases.

David also spent one year on the buy-side working at Temasek covering APAC biotech deals. Before jumping over to the investment world, he spent six years as a bench scientist at Merck and Pfizer, developing immuno-oncology drugs to support their pipelines. David holds an MBA from University of Chicago Booth School of Business, an MA in Biotechnology from Harvard University, and a BSc in Cell and Molecular Biology from University of British Columbia.



Panelists



Allan Shaw
Director,
Evecxia Therapeutics, Inc.

Five-time public company CFO and seven-time public company director with 25+ years of capital markets, governance and operating leadership.

Experience spans global commercial biopharma Serono S.A. (NYSE: SRA/SWX: SEO) and early-stage, clinical companies such as CREATE Medicines, CalciMedica (Nasdaq: CALC), Evecxia Therapeutics, Portage Biotech (NASDAQ: PRTG), and Syndax Pharmaceuticals (Nasdaq: SNDX).

Played senior leadership role in \$4B+ of public and private financings, including IPOs, follow-ons, convertibles, preferred equity, high yield debt, and structured credit. Supported \$1.2B+ in strategic transactions spanning M&A, collaborations, and licensing agreements.

Board-level partner to CEOs, directors and senior leadership teams in aligning financial discipline with scientific innovation across multiple therapeutic areas and modalities.

Proven ability to articulate the “story of the science” to investors, bankers and analysts while navigating complex strategic and operational decisions that drive enterprise value. Experience also includes leadership roles in international shipping and communications as well as career foundation in public accounting at Deloitte.



Carla Lema Tome
PhD, MBA
VP of Business Development,
Otsuka Pharmaceutical
Companies (U.S.)

Carla Lema Tome is a VP of Business Development at Otsuka Pharmaceuticals, working globally with colleagues in Japan and Europe and leading the US based team. In this role, she and her team are responsible for the global search, scientific evaluation, business case preparation and negotiation of assets, research programs and platforms from early research to late clinical development and commercial stages.

She was previously at Spark Therapeutics, a member of the Roche group, as a Senior Director of Business Development focusing on Neuroscience, Ocular, and Platform Technologies opportunities.

Carla has had roles as a Commercial and Medical Strategy consultant and as Therapeutic Strategy Lead working with pharmaceutical and medical device companies focused on the CNS space to develop integrated clinical development plans, evaluating assets and markets, and supporting launch planning.

Carla has a PhD in Neurobiology and Anatomy and an MBA, both from Wake Forest University and has completed two postdoctoral fellowships in the Brain Tumor Center of Excellence at Wake Forest School of Medicine, and in the Department of Experimental Medicine at Lund University.

Carla maintains an Adjunct Assistant Professor's appointment at Wake Forest School of Medicine where she lectures on neurotech commercialization, developmental neuroscience, and regulatory affairs.



Panelists



Fernando Salles, PhD
Chief Business Officer,
Protalix Biotherapeutics

Dr. Fernando ("Fern") Sallés is a biopharmaceutical executive with > 25 years of experience in strategic business development, licensing, and strategy. Through his consulting firm, Pteropsida Ventures, LLC, he serves as a fractional Chief Business Officer to biotechnology and pharmaceutical companies, supporting a broad range of activities including business development strategy, out-licensing, in-licensing, partnerships, and fundraising.

Fern currently advises and supports several organizations, including Protalix Biotherapeutics, AgeneBio, and InventisBio. Most recently, he led the execution of a discovery-stage collaboration with Secarna Pharmaceuticals focused on rare kidney diseases.

Prior to consulting, Fern served as Chief Business Officer at Kallyope, where he led the acquisition of a Phase 2b-ready clinical asset from Mitsubishi Tanabe Pharma. Previously, as Senior Vice President and Head of U.S./EU Business Development at I-Mab Biopharma, he co-led negotiations with AbbVie for the ex-Greater China partnership of I-Mab's innovative CD47 antibody program. The transaction received the 2020 BioCentury/BayHelix Healthcare Deal of the Year Award and contributed to I-Mab's growth from approximately \$900 million to more than \$5 billion in market capitalization.

Throughout his career, Fern has held senior leadership positions across business development and corporate strategy at Teva Pharmaceuticals, Merck, Schering-Plough, and Organon.



Blair Bu
Senior Partner,
IntelliPro

Blair Bu is the Global Senior Partner for Life Sciences and Healthcare at IntelliPro Group, where she leads a dynamic team of over 100 professionals across various regions and countries. With more than a decade of experience in executive search, Blair has developed a deep expertise in the global healthcare sector, particularly in pharmaceuticals and medical devices. Her strategic acumen has facilitated significant international collaborations, with a focus on key markets including China, the United States, Singapore, and Europe. Blair's leadership is instrumental in advancing IntelliPro Group's global initiatives, solidifying its presence in the life sciences and healthcare sectors.



Sino-American
Pharmaceutical
Professionals
Association

2026 SAPA HEALTHCARE INVESTMENT
FORUM & ROADSHOW

BD Decision Intelligence

Speaker



Junchi Lu, PhD
Associate Director,
Bristol Myers Squibb

Junchi Lu is an Associate Director at Bristol Myers Squibb, where she architects AI and advanced analytics solutions across the Global Supply Chain — spanning network supply AI agents, predictive risk assessment, and clinical supply forecasting. As a hybrid professional at the intersection of data science, supply chain strategy, and patient impact, she specializes in solving the problems no single function can solve alone: the ones that arise when moving life-saving products from development to patients.

Her career reflects a deliberate journey across science, technology, and business. A Ph.D. in Electrical Engineering from Notre Dame, where her nanophotonics research pioneered infrared medical devices, gave her the technical rigor to work at the limits of hard problems. Years in life sciences strategy consulting and incubator environments sharpened the market instincts that now define her approach to AI deployment in large pharma.

Recognized with BMS's Business Insights & Technology Innovation Award, Junchi and her cross-functional team drove measurable business value through AI-enabled supply chain analytics — bridging clinical, commercial, and operations stakeholders around a shared strategic vision.

She leads Sino-American Pharmaceutical Professionals Association (SAPA)'s Global Communication team, has hosted 30+ episodes of the SAPA 8@8 career series, and delivered 10+ AI workshops helping practitioners cultivate their "Edge" collaboration.

AI-Powered Drug Asset Valuation for Pharma Business Development

- ❑ Pharma BD diligence takes weeks. Competitive deals don't wait.
- ❑ BD Decision Intelligence is a multi-agent AI system that turns an asset name into a full diligence package — science profile, competitive benchmarking, deal valuation, and strategic buyer map — in minutes. Every assumption is transparent and editable in real time.
- ❑ Validated against 27 real 2025–2026 M&A transactions, the system's valuations track actual deal prices within 20–30%.
- ❑ For BD leaders and investment decision-makers: faster deal screening, more defensible valuations, and live scenario modeling at the negotiating table — accelerating every stage from opportunity identification to term sheet.
- ❑ Live demo included.



Sino-American
Pharmaceutical
Professionals
Association

2026 SAPA HEALTHCARE INVESTMENT
FORUM & ROADSHOW

Roadshow

Moderator



Han Zhang, PhD
Managing Director,
Boston Capital Investment Club

Han Zhang, PhD is the Managing Director of Boston Capital Investment Club (BCIC), where he supports connections among biotech founders, investors, and strategic partners across the life sciences ecosystem. Earlier in his career, Han was part of the founding team at Annoroad Gene Technology and contributed to the company's growth through its IPO journey. With training in biomedical informatics and a strong interest in commercialization strategy, Han focuses on bridging scientific innovation with market insight, partnering strategy, and investment dialogue.

Companies

7 Hills Pharma



7 Hills Pharma is a clinical-stage drug development company advancing first-in-class integrin-targeted agonists designed to safely augment immunotherapies for the treatment of cancer and genetic diseases.

Clinical-stage / Biotech developing oral small_x0002_molecule integrin agonists to augment immunotherapy and stem-cell transplantation.

Diapin Therapeutics



Diapin is a clinical-stage drug development company developing novel therapeutics for the treatment of stroke, myocardial infarction, MASH, primary biliary cholangitis, familial partial lipodystrophy, and Type 2 diabetes.

Clinical-stage / University of Michigan spinout in cardiovascular and metabolic diseases.

ACON Pharmaceuticals



ACON Pharmaceuticals possesses a world-leading, AI-driven technology platform for nucleic acid drug design and delivery. Its independently developed GalNAc technology platform is utilized to develop siRNA therapies for the treatment of hemophilia and hypertension. The company's proprietary lung-targeting LNP delivery system for siRNA drugs—encompassing both inhaled and injectable siRNA formulations—is being developed to treat pulmonary fibrosis (IPF) and other respiratory diseases. Furthermore, its patented ACP technology facilitates the delivery of siRNA across the blood-brain barrier (BBB) for the treatment of Alzheimer's disease (AD) and other CNS disorders.

Additionally, the company employs a patented long-acting microsphere technology for the treatment of schizophrenia. The company is currently seeking to raise US\$ 5 million in funding to advance these projects; within one year, these programs are projected to complete their IND submissions of IPF and hemophilia, enter clinical trials, and emerge as "First-in-Class" and "Best-in-Class" products poised to capture multi-billion-dollar market opportunities.



Sino-American
Pharmaceutical
Professionals
Association

2026 SAPA HEALTHCARE INVESTMENT
FORUM & ROADSHOW

Together We Achieve



Title Sponsor



From Data to Intelligence

PRINCETON, NEW JERSEY
USA

Enterprise AI Solutions

AI that transforms enterprise
operations into **intelligence**.

www.opaida.ai



PRODUCTS

1



Life Science QA/QC

Accelerate quality
and compliance
with AI.

2



Manufacturing Quotation

Smart, AI-powered
quotations for faster
decisions.

3



RFI/RFP

Automate responses.
Win more bids
with AI precision.

4



Unified Data Agent (UDA)

Unify, manage, and
activate your data
intelligently.

INDUSTRIES WE EMPOWER



HEALTHCARE &
LIFE SCIENCES



FINANCE &
BANKING



GOVERNMENT
SYSTEMS



MANUFACTURING

TECHNOLOGY THAT DELIVERS



SECURE PRIVATE AI

Your Data.
Your Control.



HIGH EFFICIENCY

Optimizes Models.
Faster Results.



90%+ COST REDUCTION

Lower Costs.
Higher Impact.



HALLUCINATION CONTROL AI

More Accurate.
More Reliable.

ABOUT US

IntelliPro Group (IPG), established in 2009 in Silicon Valley, USA, is a leading provider of integrated HR solutions. IPG focuses on creating a global AI-driven talent platform, offering comprehensive HR services for enterprises expanding overseas, from recruitment to employment.

IntelliPro Bio, a division of IPG, specializes in tailored talent solutions, HR services, and consulting for the Life Sciences and Healthcare industries, including executive search, global expansion support, and investment and financing services.

CORPERATE BUSINESS



MISSION

Committed to building a globally leading AI-driven platform for efficient talent matching and development.



VISION

Empowering global enterprises to thrive worldwide.



Talent Solutions

Executive Search
RPO
Staffing



HR Solutions


EOR/PEO/HRO
HR Compliance
Global Mobility



Consulting Solutions

Global Expansion
Financial Advisory
Strategic Consulting

GLOBAL SERVICE COVERAGE





Support Team

President Office	Wei Ding Lily Li Jack Wu	SAPA Board of Directors	Larry Cai, Xiaodong Chen, Xin Du, Frank Xiaodong Gan, Junyan Hong, Min Li, Yongmei Li, Jerry Liu, Jian Liu, Xiaole Shen, Jerica Bin Shi, Mingde Xia, Jing Yang, Yan Yan, Chao Zheng, Charles Li, Feng Liu, Zhenhua Wu, Haichen Yang, Bill Shifeng Wei, Hancheng Zhang, Alex Li, Peng Sun, Jack Wu, Wei Ding
Event Chairs	Stephen Xue Lily Li Xiaodong Chen		
Finance	Aiguo Xu Ellen Chen		
Fundraising	Yongle Pang Yang Wang Jessica		
IT	Brian Jiang Xi Cheng Yifeng Liang Feiyi Sun Jason Zhong Qi Song		
Communica-tions	Junchi Lu, Yannan Liu, Xiaoqi Wu, Midan Ai, Wenyu Jiao, Judy Wei, Chelsea Gu, Qi Wang, Siyu Jiang, Xiaoqi Wu, Qi Wang, Judy Wei, Emmy Ai, Wenyu Jiao, Yupu Qiao, Wendi Ma, Ada Wu, Lisheng Zhou, John Wei, Shihan Xu, Shengjie Xu, Tao Zhang, Yang Ge, Chelsea Gu, Wen Shi, Yun Zhang	On-site Operation & Logistics	Xuguang Chen Helena Wang Kellen Xu Xiaowei Sun Jiangchao Chen Jayna Gao Selena Xianglong Zhu Wendi Ma Hongrui Liu Emma Lu Yingchun Zhao Linsey Zhang Mengwen Shi Lily Li Xin Huang Yun Zhang



Sino-American
Pharmaceutical
Professionals
Association

2026 SAPA HEALTHCARE INVESTMENT
FORUM & ROADSHOW

FOLLOW US



linkedin.com/company/sapa-hq



sapaweb.org



美中药协SAPA



@SAPA_HQ



CONTACT US





event@sapaweb.org

Audience
Registration

Company
Registration

BD/Investor
Application



For more inquiries, please contact: roadshow@sapaweb.org